Total Funding
33
Total FundingSeries A raised
Growth Score
pts
Heat Score
8 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
InVasc Therapeutics develops drug-based platforms for diabetes, atherosclerosis, hypertension, and cardiovascular diseases.
William D. Johnston: COO & Director- William D. Schaeffer: Chief Executive OfficerPast Role: InVasc Therapeutics, Chief Operating Officer
About the Company
InVasc Therapeutics was founded in 2006 by three leading researchers at Emory University and Ohio State University. These three researchers began their fifteen-year research and clinical collaboration at Emory University. InVasc was formed to develop several platforms of drugs to combat cardiometabolic conditions such as diabetes, atherosclerosis,
hypertension and cardiovascular diseases and their complications. In the spring of 2010, the Company transitioned from an early phase start up led by academic researchers to a development organization by adding two senior executives with more than 70 years of combined executive and product development experience in the pharmaceutical, medical device and biotechnology industry.
